8:00 a.m. – 8:05 a.m.

Welcome

• (In-person) Sudhir Srivastava, PhD, MPH, National Cancer Institute
• (In-person) Arul Chinnaiyan, MD, University of Michigan Medical School
• (In-person) Karen Anderson, MD, PhD, Arizona State University/The Biodesign Institute

8:05 a.m – 8:35 a.m.

01: Keynote #2: TMIST- How It Is Addressing the Most Important Issues in Breast Cancer Screening

(In-person) Etta Pisano, MD, FACR, American College of Radiology

8:35 a.m. – 8:40 a.m.

Q&A

8:40 a.m. – 9:10 a.m.

02: Keynote #3: How Place and Space Enhances Biomarkers (ZNA Matters)

(Virtual) Robert Winn, MD, Virginia Commonwealth University

9:10 a.m. – 9:15 a.m.

Q&A

9:15 a.m. – 9:35 a.m.

Break

9:35 a.m. – 11:50 a.m.

Session 4: Cancer Early Detection in Prevention Research in Other NCI Consortia

9:35 a.m. – 9:45 a.m.

03: Introduction to the Session

Moderator: (In-person) Sudhir Srivastava, PhD, MPH, National Cancer Institute

9:45 a.m. – 10:05 a.m.

04: Blood Based Strategies for Early Detection and Intervention for Precision Cancer Management: The View from the NCI Liquid Biopsy Consortium

(In-person) Richard Cote, MD, Washington University School of Medicine in St. Louis

Liquid Biopsy Consortium

10:05 a.m. – 10:10 a.m.

Q&A

10:10 a.m. – 10:30 a.m.

05: Transforming the Management of Early Breast Cancer Detection: Insights from the HTAN Precancer Atlas

(In-person) Shelley Hwang, MD, MPH, Duke University

Human Tumor Atlas Network (HTAN)

10:30 a.m. – 10:35 a.m.

Q&A

10:35 a.m. – 10:55 a.m.

06: Experience with early pancreatic cancer detection in the CAPS Study

(In-person) Michael Goggins, MD, Johns Hopkins University

Pancreatic Cancer Detection Consortium

10:55 a.m. – 11:00 a.m.

Q&A

11:00 a.m. – 11:20 a.m.

07: Molecular Pathology of Prostate Cancer Precursor Lesions

(In-person) Angelo DeMarzo, MD, PhD, Johns Hopkins University

Translational and Basic Science Research in Early Lesions

11:20 a.m. – 11:25 a.m.

Q&A

11:25 a.m. – 11:45 a.m.

08: Defining Biomarkers of the Malignant Progression of the Benign Plasma Cell Dyscrasia, Monoclonal Gammopathy of Undetermined Significance (MGUS)

(Virtual) John D. Shaughnessy, PhD, University of Arkansas for Medical Sciences

Cancer Prevention-Interception Targeted Discovery Program (CAP IT)

11:45 a.m. – 11:50 a.m.

Q&A

11:50 a.m. – 1:30 p.m.

Lunch (On Your Own)

1:30 p.m. – 3:20 p.m.

Session 5: Preanalytical Variables in Biomarker Research

1:30 p.m. – 1:40 p.m.

09: Introduction to the Session

Moderator:(In-person) Joshua LaBaer, MD, PhD, Arizona State University/The Biodesign Institute

1:40 p.m. – 2:00 p.m.

10: Preanalytical Challenges for ctDNA Measurements – Where are We Now?

(In-person) Hua-Jun He, PhD, National Institute of Standards and Technology

2:00 p.m. – 2:05 p.m.

Q&A

2:05 p.m. – 2:25 p.m.

11: Optimizing Cancer Detection with IVDs

(In-person) Timothy Stenzel, MD, PhD, Office of in Vitro Diagnostics, Food and Drug Administration

2:25 p.m. – 2:30 p.m.

Q&A

2:30 p.m. – 2:50 p.m.

12: Preanalytical Aspects of Biomarker Discovery and Validation

(In-person) Martin Stengelin, PhD, MBA, Meso Scale Diagnostics

2:50 p.m. – 2:55 p.m.

Q&A

2:55 p.m. – 3:15 p.m.

13: EDRN BRL: A Critical Building Block for the Development of Cancer Diagnostics

(In-person) Daniel Chan, PhD, Johns Hopkins University

3:15 p.m. – 3:20 p.m.

Q&A

3:20 p.m. – 3:45 p.m.

Break

3:45 p.m. – 4:05 p.m.

14: Clinical development of apolipoprotein A2-isoforms for early detection and risk stratification of pancreatic cancer

(Virtual) Kazufumi Honda, DDS, PhD, Nippon Medical School

4:05 p.m. – 4:10 p.m.

Q&A

4:10 p.m. – 5:10 p.m.

Session 6: Panel Discussion: Single versus Multiple Biomarkers

Panelists:

• (In-person) Ziding Feng, PhD, Fred Hutchinson Cancer Center
• (In-person) Samir Hanash, MD, PhD, MD Anderson Cancer Center
• Giulia Kennedy, PhD, Acumark Diagnostic
• (In-person) Joshua LaBaer, MD, PhD, Arizona State University/The Biodesign Institute
• (In-person) Martin Sanda, MD, Emory University
• (In-person) Stephen Deppen, PhD, Vanderbilt University Medical Center

5:10 p.m. – 6:30 p.m.

15: Session 7: There’s More to Cancer Biomarkers than the Circulation

Moderator: (In-person) Karen Anderson, MD, PhD, Arizona State University/The Biodesign Institute

5:10 p.m. – 5:30 p.m.

16: Imaging Markers of Breast Cancer Risk

(In-person) Savannah Partridge, PhD, University of Washington

5:30 p.m. – 5:35 p.m.

Q&A

5:35 p.m. – 5:55 p.m.

17: Real-time Metabolic Imaging for Early Detection of Pancreatic Cancer

(In-person) Pratip Bhattacharya, PhD, The University of Texas MD Anderson Cancer Center

5:55 p.m. – 6:00 p.m.

Q&A

6:00 p.m. – 6:20 p.m.

18: NYU BCC: Microbial and host biomarker development for detection and prognosis of early stage non-small cell lung cancer

(In-person) Leopoldo Segal, MD, New York University Grossman School of Medicine

6:20 p.m. – 6:25 p.m.

Q&A

6:25 p.m.

Adjourn Scientific Workshop

(In-person) Sudhir Srivastava, PhD, MPH, National Cancer Institute

7:00 p.m. – 9:00 p.m.

Ad-hoc EDRN Executive Committee Meeting (CLOSED)